PE-22-28
Also known as Spadin analog, TREK-1-related peptide
A short peptide analog discussed in neuropsychiatric research for TREK-1 potassium-channel biology, antidepressant-like mechanisms, and neuroplasticity models.
Overview
PE-22-28 is a short peptide discussed as a spadin-related analog in neuropsychiatric research. It is not an approved antidepressant; it is a research peptide tied to ion-channel and neuroplasticity hypotheses.
The Science
The research focus is TREK-1, a potassium channel implicated in neuronal excitability and mood-related signaling.
- TREK-1 modulation - ion-channel target biology.
- Antidepressant-like models - mostly preclinical behavioral research.
- Neuroplasticity - interest in synaptic and stress-response pathways.
Evidence Snapshot
PE-22-28 is early-stage and mechanism-driven. Human clinical interpretation is premature without controlled studies.
Related
More in Cognitive
Adamax
Research compoundCognitive
A Semax-derived cognitive research peptide marketed in nootropic communities, with claims centered on neurotrophic signaling, focus, mood, and stress resilience.
Cerebrolysin
InvestigationalCognitive
A parenteral preparation of small peptides and amino acids derived from porcine brain protein, used clinically for decades across stroke, dementia, and traumatic brain injury recovery in many countries outside the US.
Dermorphin
Research compoundCognitive
A potent opioid heptapeptide originally isolated from frog skin secretions and studied as a tool compound for mu-opioid receptor pharmacology and analgesia research.